PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-21.98%
Both yoy net incomes decline, with AXSM at -8.17%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
22.78%
Less D&A growth vs. AXSM's 54.32%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
128.24%
SBC growth while AXSM is negative at -9.49%. John Neff would see competitor possibly controlling share issuance more tightly.
-92.68%
Negative yoy working capital usage while AXSM is 475.26%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
314.60%
A yoy AP increase while AXSM is negative at -196.35%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
26.98%
Lower 'other working capital' growth vs. AXSM's 264.30%. David Dodd would see fewer unexpected short-term demands on cash.
-101.99%
Negative yoy while AXSM is 118.16%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-120.47%
Negative yoy CFO while AXSM is 32.14%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
72.96%
CapEx growth well above AXSM's 72.64%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.96%
Investing outflow well above AXSM's 99.88%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
86.96%
Debt repayment at 75-90% of AXSM's 98.91%. Bill Ackman urges more debt clearance to match competitor’s lower leverage.
-90.54%
Negative yoy issuance while AXSM is 453.60%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.